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Ghrelin, by binding growth hormone secretagogue receptor (GHS-R), promotes osteoblast proliferation but the signaling
mechanism of GHS-R on these cells remains unclear. Since canonical Wnt/𝛽-catenin pathway is critically associated with bone
homeostasis, we investigated its involvement in mediating ghrelin effects in osteoblasts and in osteoblast-osteoclast cross talk.
Ghrelin (10−10M) significantly increased 𝛽-catenin levels in rat osteoblasts (rOB). This stimulatory action on 𝛽-catenin involves
a specific interaction with GHS-R1a, as it is prevented by the selective GHS-R1a antagonist, D-Lys3-GHRP-6 (10−7M). The effect
of ghrelin on 𝛽-catenin involves the phosphorylation and inactivation of GSK-3𝛽 via protein kinase A (PKA). Inhibition of PKA
activity reduces the facilitatory action of ghrelin on 𝛽-catenin stabilization. Ghrelin treatment of rOB significantly increases the
expression of osteoprotegerin (OPG), which plays an important role in the regulation of osteoclastogenesis, and this effect is
blocked by D-Lys3-GHRP-6. Furthermore, ghrelin reduced RANKL/OPG ratio thus contrasting osteoclastogenesis. Accordingly,
conditioned media from rOB treated with ghrelin decreased the number of multinucleated TRAcP+ cells as compared with the
conditioned media from untreated-control rOB. Our data suggest new roles for ghrelin in modulating bone homeostasis via a
specific interaction with GHSR-1a in osteoblasts with subsequent enhancement of both 𝛽-catenin levels and OPG expression.
1. Introduction
Accumulating evidence, including in vitro and in vivo studies
in animal models as well as observational studies in humans,
indicate a role for ghrelin in the control of bone cell activities
[1–4].
Ghrelin, an endogenous ligand of the GH secretagogue
receptor (GHS-R), and its receptor GHS-R1a are expressed in
several osteoblasts and osteoblastic cell lines. Ghrelin directly
promotes both osteoblast proliferation and differentiation [5–
8] and inhibits apoptosis of MC3T3-E1 cells [6, 9]. Moreover,
recent data suggest that GHS-R1a expression is subjected
to an epigenetic regulation through DNA methylation and
histone modification. Changes in the epigenetic status of the
cell might therefore play an important role in determining
sensitivity to ghrelin [10].
In addition to a well characterized anabolic action, the
data regarding the effects of ghrelin on osteoclastogenesis
are contradictory. Costa et al. [8] have shown that ghrelin
increases the bone resorption activity of rat osteoclasts but
did not modify osteoclast differentiation in a murine bone
marrow assay or bone resorption in ex vivo calvarial culture.
More recently, van der Velde et al. [11] found that ghrelin
has dual actions in osteoclasts since it inhibits osteoclast
progenitors locally and exerts an age-dependent stimulatory
action on osteoclastogenesis via a systemic pathway.
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In vivo studies showed that intraperitoneal [5] as well as
central administration [12] of ghrelin increases bone mineral
density and mass through a mechanism independent of GH-
IGF1 axis and appetite regulation, respectively. Consistently,
synthetic GH secretagogues increase bone mineral density
[13] and prevent gonadectomy-induced bone loss in the rat
[14, 15]. Data from clinical studies are limited but indicate
a positive association between circulating ghrelin levels and
bone mineral density in women [16, 17] and elderly men [18].
Despite convincing evidence that ghrelin has positive
effects on bone metabolism, the signaling mechanism and
the specific involvement of GHS-R1a in osteoblast are still
controversial [19] and remain unclear. Since the canonical
Wnt/𝛽-catenin pathway is critically associated with the entire
osteoblast life cycle, that is, commitment, proliferation, apop-
tosis, and function, we hypothesized that ghrelin exerts its
anabolic action in bone through canonicalWnt signaling and
𝛽-catenin stabilization. This hypothesis is supported by the
observation that in rat cortical neuron cells ghrelin exerts
specific, receptor mediated antiapoptotic effects by activating
ERK1/2 pathway and by stabilizing 𝛽-catenin via PI3K/Akt-
mediated inactivation of glycogen synthase kinase (GSK-3𝛽)
[20].
Wnt canonical signaling pathway relies on the cytosolic
stabilization of 𝛽-catenin, which is a 130 amino acid protein
that, in the absence of Wnt proteins, is phosphorylated by
GSK-3𝛽 and degraded through the proteosomal machinery.
When not degraded, stable 𝛽-catenin is accumulated in the
cytoplasm and upon reaching a certain concentration level is
translocated into the nucleus to stimulate gene transcription
[21].
To test our hypothesis, we first examined the effects of
increasing concentrations of ghrelin on 𝛽-catenin intracellu-
lar levels in primary rat osteoblasts. Then, we characterized
the receptor involved in the stimulatory action of ghrelin on
𝛽-catenin and examined the effects of ghrelin on the expres-
sion of osteoprotegerin (OPG) a target gene of 𝛽-catenin that
plays an important role in osteoblasts and osteoclasts cross
talk. Furthermore, we evaluated whether or not ghrelin, by
modulating the OPG/RANKL/RANK system, could influ-
ence osteoclastogenesis in cultured rat osteoclast precursors
cells.
2. Materials and Methods
2.1. Drugs. Ghrelin was synthesized by conventional solid
phase synthesis and purified to at least 98% purity by HPLC
by Neosystem (Strasburg, France). D-Lys3-GHRP-6 was pur-
chased from BachemAG (Dubendorf, Switzerland). H89 was
from Sigma,Milan, Italy. Ratmacrophage colony-stimulatory
factor (M-CSF) and rat RANKL were from Peprotech, Rocky
Hill, NJ.
2.2. Rat Osteoblast-Like Cells. Parietal and frontal calvariae
(4 per animal) were explanted aseptically from 3-day-old
Sprague Dawley rats. After removing the periosteum, the cal-
variae were cut in small pieces and placed in Joklik’s modified
MEM (Sigma, Milan, Italy) serum-free medium containing
0.5mg/mL type IV collagenase (Sigma, Milan, Italy) for 20
minutes at 37∘C with rotation. Digestion was stopped by the
addition of Dulbecco’s medium (DMEM, Euroclone, Milan,
Italy) containing 10% foetal bovine serum (FBS, Euroclone).
Calvariae obtained from three animals were plated in 75 cm2
flask and allowed to grow to confluence inDMEMcontaining
10% FBS, 100U/mL penicillin, 100mg/mL streptomycin,
and 0.25mg/mL amphotericin B; the culture medium was
changed every 2-3 days. Cells reached confluence after
approximately one week. The cell population was tested for
alkaline phosphatase production after PTH 10−8M treatment
for 48 h to ensure that the cells were endowed with osteoblast
characteristics. Cells were all used at first passage to reduce
the possibility of phenotype changes.
2.3. Cell Viability Assay. Cells were plated at the density of 3×
103 cells/well in a 96-well culture plate. After treatment, cells
were washedwith phosphate buffered saline (PBS, Euroclone,
Italy) and incubated at 37∘Cwith 0.5mg/mL 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyltetrazoliumbromide (MTT, Sigma-
Aldrich Chemical, Italy) for 3 h. The conversion of the tetra-
zolium salt MTT to a colored formazan was used to assess
cell viability. After the supernatant was removed, dimethyl
sulfoxide was added to each well and the absorbance was
recorded by a microplate spectrophotometer (WALLAC) at
550 nm.
Cell phenotypic observations were made using Olympus
TH4-200 inverted phase-contrast microscope, fitted with a
digital camera Olympus C-4040 zoom to record any change
during treatment.
2.4. Western Blot Analysis. Confluent cells plated in 6-well
multiwell plates were treated with ghrelin 10−11–10−7M for
15, 30, 60, 90, and 120min; the GHSR1a receptor antagonist,
D-Lys3-GHRP-6 (10−7M), was added 30min before ghrelin
10−10M; incubation with 2×10−6MH89, an inhibitor of PKA
activity, was performed 30min before ghrelin 10−10M.
After removing the medium, adherent cells were gently
scraped into 75𝜇L RIPA buffer (1% triton X100, 0.5% Sodium
deoxycholate, 0.1% Sodium Dodecyl Sulphate) per well. Two
wells were collected for each treatment. Total protein concen-
tration was determined by BCA assay (Pierce, Rockford, IL).
Thirty micrograms of total protein extract was mixed with
the appropriate volume of Laemmli’s sample loading buffer,
heated at 100∘C for 5min and loaded onto 10% SDS polyacry-
lamide gels. Western blots were performed using a specific
antibody against rat 𝛽-catenin diluted 1 : 5000 in 5% milk in
Tris–HCl with 0.1% Tween-20 (TBST); rat P-GSK3𝛽 (1 : 2000
5%milk in TBST); rat total GSK3𝛽 (1 : 2000 5%milk in TBST)
(Cell Signaling Technology, Boston, MA) or against rat 𝛽-
actin (1 : 2000 5% milk in TBST) (Santa Cruz Biotechnology,
Inc., Heidelberg, Germany). Nuclear fractions were isolated
from untreated cells or cells treated with ghrelin (10−10M)
alone or in association with D-Lys3-GHRP-6 (10−7M) by the
Qproteome Cell Compartment Assay (Qiagen SpA, Milan,
Italy) that allows selectively isolating proteins in different cell
compartments by sequential addition of different extraction
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buffers to a cell pellet. Scion Image software (Scion Corp.,
Frederick, MD) was used to quantify the Western blots. 𝛽-
Actin or Tot-GSK3𝛽 was used as endogenous controls to
avoid incorrect estimations of the signal from the protein of
interest. The intensity of the treated samples was normalized
to that of the untreated samples (set as 1) and presented as a
ratio of untreated controls.
2.5. Real-Time PCR. Osteoprotegerin (OPG), 𝛽-catenin,
receptor activator of NFkB ligand (RANKL), and Dickkopf
1 (DKK1) mRNA relative expression were evaluated by real-
time PCR after exposing rOB at confluence to ghrelin
10−11M–10−7M for 1, 4, and 24 h in serum-free medium.
In order to assess if the effect of ghrelin on OPG gene
expression was receptor mediated, cells were pretreated with
D-Lys3-GHRP-6 10−7M 30min before adding ghrelin. Total
RNA was extracted using TRIzol according to the manufac-
turer’s instructions (Invitrogen Life Technology, Inc., Paisley,
UK). RNA pellet concentrations were assessed spectrophoto-
metrically using Epoch Spectrophotometer System (Biotek)
(OD260/280). Two micrograms of total RNA were retrotran-
scribed in a total volume of 25 𝜇L using an oligodT primer
(0.5mM), 200U of M-MLV reverse transcriptase, deoxynu-
cleotides (0.5mM), M-MLV reaction Buffer 1x, and rRNasin
ribonuclease inhibitor 1 U/mL (Promega Corporation, Madi-
son, WI). Relative quantification of OPG 𝛽-catenin, RANKL,
and DKK1 was performed on an ABI PRISM 7900 sequence
detector (Applied Biosystems, Foster City, CA) using 20 ng
cDNA of the RT-PCR solution in a final volume of 25 𝜇L.
The primer-probe sets were purchased as assay-on-demand
for gene expression from Applied Biosystems. Real-time
PCR was performed with FAM-labelled specific probes for
OPG, 𝛽-catenin, RANKL, and DKK1 detection and VIC-
labelled probes for the detection of the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), used
as an endogenous control. Real-time PCR was run according
to the following protocol: an initial step of 2min at 50∘C and
10min at 95∘C followedby 40 cycles of 15 sec at 95∘Cand 1min
at 60∘C. mRNA levels were quantified using the comparative
threshold-cycle (Ct) method.
2.6. Osteoclastogenesis Assay. Osteoclast precursors cells
were obtained from 3-day-old rat pups long bones. Bone
marrow was flushed out with DMEM and the cell suspen-
sion was pushed through needles of decreasing size (19G–
25G) until homogenously resuspended. Cells were then cen-
trifuged and plated in petri dishes in DMEM supplemented
with 10% FBS, 100U/mL penicillin, 100mg/mL streptomycin,
and 0.25mg/mL amphotericin B in the presence of M-
CSF (100 ng/mL) for 48 h. Nonadherent erythrocytes were
removedwhile adherent bonemarrow cells were washedwith
PBS resuspended in culture medium and plated on 96-well
plates (104 cells/well) with M-CSF (25 ng/mL) and RANK-L
(50 ng/mL) for osteoclast generation in presence of 50% of
conditioning medium derived from rOB treated with ghrelin
10−10M for 24 h, 48 h, or untreated. Half of the media was
changed every day and cytokines were added freshly. After
5 days of culture cells were fixed with 4% paraformaldehyde
in PBS for 10min and osteoclast formation was assessed by
tartrate resistant acid phosphatase (TRAcP) staining. Briefly,
fixed cells were incubated with naphthol-ASBI-phosphate,
pararosanilin, and tartrate in acetate buffer (30 𝜇M) at 37∘C
for 45min. TRAcP positive cells with three or more nuclei
were considered to be osteoclasts.
2.7. Statistical Analysis. Statistical analysis was performed
with a statistic package (GraphPad Prism 5, GraphPad Soft-
ware San Diego, CA, USA). All data are represented as the
mean ± SEM. Differences between groups were assessed by
one-way analysis of variance (ANOVA) for nonparametric
data (Kruskal-Wallis test) followed by a multiple comparison
test (Dunn’s test) and byMann-Whitney𝑈 test when compar-
ing two groups only. A probability of𝑃 < 0.05was considered
to be significant.
3. Results
To examine the effects of ghrelin on 𝛽-catenin levels, primary
rat osteoblast-like cells were treated for 60min with increas-
ing ghrelin concentrations. Using Western blot analysis, we
have shown that ghrelin significantly increased 𝛽-catenin
levels starting from 10−10M to 10−8M (Figure 1). Although
the observed increment was small, it was dose and time
dependent, thus indicating its specificity.
The stimulatory action of ghrelin on 𝛽-catenin involves
GSK-3𝛽 phosphorylation and inactivation as shown by
the significant increase of phosphorylated GSK-3𝛽 induced
by ghrelin (10−10M) starting from 30min of incubation
(Figure 2).
In order to study whether the observed 𝛽-catenin sta-
bilization induced by ghrelin involves a specific interaction
with its GHS-R1a, primary rat osteoblast-like cells were
treated for 30min with the selective GHS-R1a antagonist,
D-Lys3-GHRP-6 (10−7M), and then challenged with ghrelin
(10−10M). 𝛽-catenin levels weremeasured in both the cytoso-
lic and nuclear compartments after fractioning of the whole
cell lysate. PretreatmentwithD-Lys3-GHRP-6 abolished both
ghrelin-induced cytoplasm 𝛽-catenin stabilization and 𝛽-
catenin nuclear migration (Figure 3), indicating that the
effects of ghrelin on𝛽-catenin are due to a specific interaction
of the peptide with GHS-R1a.
We then explored the intracellular signaling pathways
involved in the stimulatory action of ghrelin on 𝛽-catenin
levels following its binding to GHS-R1a. Our data demon-
strate that 10−10M ghrelin activates cAMP/PKA pathway
since a PKA inhibitor, H89, reduced both ghrelin-induced 𝛽-
catenin stabilization (Figure 4(a)) and GSK-3𝛽 phosphoryla-
tion (Figure 4(b)).
To further confirm that ghrelin exerts its anabolic action
by interacting with GHS-R1a via PKA activation, osteoblast
viability was assessed after pretreatment with D-Lys3-GHRP-
6 (Figure 5(a)) and after inhibition of PKA activity by H89
(Figure 5(b)). As shown, ghrelin increases significantly cell
viability whereas both pretreatments nullified it.
Considering that OPG is a target gene of 𝛽-catenin, we
examined the effects of increasing ghrelin concentrations
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Figure 1: Representative Western blot (a) and quantification (b) of the effect of increasing concentrations of ghrelin (AG, 10−11–10−7M, 1 h
treatment) on 𝛽-catenin protein level in whole cell lysates of rat osteoblast-like cells. 𝛽-catenin levels are normalized on 𝛽-actin protein levels
and results are expressed as the ratio of 𝛽-catenin amount measured in treated cells to the amount obtained in untreated cells. Data are the
mean ± SEM of five experiments ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 versus untreated cells.
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Figure 2: Representative Western blot (a) and quantification (b) of timecourse experiments performed on rat osteoblast-like cells treated
with ghrelin (AG, 10−10M) for 15, 30, 60, and 90min. Phosphorylated-GSK-3𝛽 (P-GSK-3𝛽) levels were measured in whole cell lysates and
normalized to total GSK-3𝛽 levels (Tot-GSK3𝛽). Results are shown as ratio of P-GSK3𝛽measured in treated versus untreated cells. Data are
the mean ± SEM of 5 experiments ∗𝑃 < 0.05, versus untreated cells.
on the expression of OPG, 𝛽-catenin, and DKK1 measured
by real-time PCR. Primary rat osteoblast-like cells treated
for 24 h with ghrelin (10−10M) showed a significant increase
in the expression of OPG. This ghrelin action involves an
interaction with GHS-R1a since it was removed by pretreat-
ment with D-Lys3-GHRP-6 (Figures 6(a) and 6(b)). We next
examined the effects of increasing ghrelin concentration on
RANKL expression. Ghrelin had no significant effect on
RANKLmRNA but significantly reduced RANKL/OPG ratio
at 10−10M (Figure 6(c)). No significant effect on 𝛽-catenin
andDKK1 expressions at 1, 4, and 24 h of exposure to different
doses of ghrelin (from 10−11M to 10−7M)was found (data not
shown).
To test the involvement of ghrelin in the regulation of
osteoclastogenesis, due to its stimulatory action on OPG
expression, we examined the effects of conditioned media
from rat osteoblasts treated with ghrelin, on osteoclast pre-
cursors. Osteoclast precursors cells were obtained by bone
marrow of long bones and cultured for seven days in con-
ditioned media obtained from rOB treated with or without
Ghrelin 10−10M for 24 and 48 h, in the presence of M-CSF
(25 ng/mL) and of a subeffective dose of RANKL (50 ng/mL).
The presence of osteoclast-like cells was evaluated by count-
ing the number of multinucleated TRAcP positive cells per
well. The number of osteoclasts was significantly reduced as
comparedwith that detected incubating osteoclast precursors
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Figure 3: RepresentativeWestern blot (a) and quantification (b) of 𝛽-catenin levels in the enriched nuclear fraction of rat osteoblast-like cells
exposed to ghrelin (AG, 10−10M for 1 and 2 h) alone or together with D-Lys3-GHRP-6 (D, 10−7M 30min before AG), a GHSR-1a receptor
antagonist. 𝛽-catenin levels are normalized on 𝛽-actin protein levels and results are expressed as the ratio of 𝛽-catenin amount measured in
treated cells to the amount obtained in untreated cells. Data are the mean ± SEM of five experiments ∗∗𝑃 < 0.01 versus untreated; §𝑃 < 0.05
versus 2 h AG treated cells.
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Figure 4: Effect of the pretreatment with the PKA inhibitor H89 (2×10−6M, 30min before) on (a) 𝛽-catenin and (b) phosphorylated-GSK3𝛽
(P-GSK3𝛽) levels measured in whole cell lysates by Western blot on rat osteoblast-like cells (rOB) treated with ghrelin (AG, 10−10M for 1 h).
𝛽-catenin levels were normalized to 𝛽-actin levels; P-GSK3𝛽was normalized to total GSK3𝛽 levels (Tot-GSK3𝛽). Results are expressed as ratio
of 𝛽-catenin or P-GSK3𝛽 measured in treated cells versus untreated cells. Insets: typical gels obtained from rOB cell lysates after treatment
with ghrelin alone or together with H89. Data are the mean ± SEM of 5 experiments ∗𝑃 < 0.05 versus untreated cells; §𝑃 < 0.05 versus AG
treated cells.
6 International Journal of Endocrinology
0
25
50
75
100
125
150
175
Untreated AG D + AG  D
C
el
l v
ia
bi
lit
y 
(%
 o
f c
on
tro
l) ∗
§
(a)
0
25
50
75
100
125
150
175
Untreated AG H89 + AG  H89
C
el
l v
ia
bi
lit
y 
(%
 o
f c
on
tro
l) ∗
§
(b)
Figure 5: Effect of pretreatment with (a) D-Lys3-GHRP-6 (D, 10−7M, 30min before AG) or (b) the PKA inhibitor H89 (2 × 10−6M, 30min
before AG) on the stimulatory action of ghrelin (AG, 10−10M) on rat osteoblast-like cells (rOB) viability. Cell viability was measured by MTT
assay. Data are expressed as the percentage relative to control and are the means ± SEM of four replicates within a single experiment that was
repeated at least three times. ∗𝑃 < 0.05 versus untreated cells; ∘𝑃 < 0.05 versus AG.
with medium from untreated-control osteoblasts, when bone
marrow precursors were exposed to conditioned media from
48 h ghrelin- (10−10M) treated rOB, (Figure 7).
4. Discussion
In the present studywe have shown that the anabolic action of
ghrelin involves an increase in the𝛽-catenin levels in primary
rat osteoblastic cells.This effect is mediated by GHS-R1a as its
specific antagonist, D-Lys3-GHRP-6, blocks it. Our findings
indicate that the effect of ghrelin on 𝛽-catenin accumulation
is due to inhibition of GSK-3𝛽 activation via cAMP/PKA
pathway since the inhibition of the enzyme activity by H89
reduces ghrelin activity. Consistently with the activation
of Wnt signaling, ghrelin also increases the expression of
OPG and decreases RANKL/OPG ratio leading to reduced
osteoblast-related osteoclast formation.
Several studies have shown anabolic action of ghrelin on
bone [5–7]; however the mechanisms for this effect remain
to be fully elucidated. One possible mechanism includes
the secretagogue action of ghrelin on growth hormone [22].
However, it is unlikely that the effects of ghrelin on bone
are exclusively mediated through a GH/IGF-1 axis since
ghrelin administration increases bone mass in genetically
GH-deficient rats [5].
Conversely, our study was based on the hypothesis that
ghrelin, acting on osteoblasts, could exert a direct anabolic
action through an autocrine/paracrine way that involves
Wnt/𝛽-catenin canonical pathway: a critical signaling con-
trolling osteoblasts at different levels, that is, commitment,
proliferation, apoptosis and function [23]. In the absence
of active Wnt ligands, 𝛽-catenin is bound to the scaffold
proteins Axin and adenomatous polyposis coli (APC) and
constitutively phosphorylated via interaction with casein
kinase I and GSK3-𝛽. The presence of Wnt ligands inhibits
the kinase activity of GSK-3𝛽 leading to 𝛽-catenin accumu-
lation in the cytoplasm followed by its translocation into
the nucleus where it interacts with T cell factor/lymphoid
enhancer family members to induce the transcription of key
osteoblastic genes [24]. Canonical Wnt signaling is crucial
for osteoblastogenesis and bone formation since loss or gain
of function of 𝛽-catenin is associated with a decrease or an
increase of bone mass, respectively [25]. Here we showed
that ghrelin increased 𝛽-catenin cytoplasmic levels leading
to the nuclear translocation of the protein. The effect was
obtained under physiological dosages of ghrelin to show its
fine regulation of bone cells; its magnitude was in agreement
with data recently observed in other systems [26]; it was dose
and time dependent and it was consistent with the inhibition
of GSK-3𝛽: a critical element of 𝛽-catenin activation.
The observation that ghrelin increases GSK-3𝛽 phos-
phorylation (Figure 2(a)) suggests that ghrelin promotes 𝛽-
catenin stabilization by downregulating its inhibitory path-
way.Our data are in agreementwith previous studies showing
that the activation of phosphorylated GSK-3𝛽/𝛽-catenin
activity is involved in the beneficial effects of ghrelin against
hypoxia-induced pulmonary hypertension in the rat [27] and
ischemic neural injury [20, 28]. In our study, the direct effect
of PKA on GSK-3𝛽 was documented since H89 nullified
ghrelin effect on GSK-3𝛽 activity. The direct effect of PKA
on 𝛽-catenin phosphorylation and degradation seems to be
ruled out on the basis of the present results showing that
pretreatment with H89 increased 𝛽-catenin level instead of
reducing it.
Moreover, our results sustain the emerging view that sev-
eral classes of hormones and peptides activate 𝛽-catenin
signaling through PKA dependent inhibition of GSK-3𝛽 as
was demonstrated for PTH [29] and calcitonin gene related
peptide [30]. The activation of Wnt signaling through GSK-
3𝛽 inhibition and vice versa is in fact becoming a critical
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Figure 6: Effect of increasing concentrations of ghrelin (AG, 10−11M–10−7M) on osteoprotegerin (OPG) expression measured by real-time
PCR at 24 h after AG treatment in primary cultures of rat osteoblast-like cells (a). Effect of pretreatment (30min before) with the GHSR-1a
antagonist D-Lys3-GHRP-6 (D, 10−7M) on the stimulatory action of AG (10−10M for 24 h) on OPG expression (b). Ratio of RANKL/OPG
relative expressionmeasured in untreated and AG 10−10M treated rat osteoblasts after 24 h (c). OPG and RANKL expression were normalized
to that of GAPDH and expressed as 2−ΔΔCt.Three replicates were performed for each experimental point and experiments were repeated three
times. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01 versus untreated cells. §§§𝑃 < 0.001 versus AG treated cells.
element for the full understanding of the anabolic role ofWnt
[31]. Besides the possible involvement of a receptor other than
GHS-R1a in ghrelin dependent bone metabolism regulation
[19], our study has demonstrated the importance of GHS-R1a
in the activation of the Wnt signaling in osteoblast.
Considering that GHS-R1a has been identified in osteo-
blasts [1, 7] and that at the moment the only acknowledged
ghrelin receptor is GHS-R1a, we examined the involvement of
this receptor in the stimulatory action of ghrelin on𝛽-catenin
levels. GHS-R1a involvement was proven by the fact that the
specific GHS-R1a antagonist, D-Lys3-GHRP-6, abolished the
stimulatory action of ghrelin on 𝛽-catenin, indicating that
this ghrelin effect is GHS-R1a- mediated.These results fit also
well with the report that GHS-R1a is involved in the stim-
ulatory action of ghrelin on osteoblast proliferation [5]
and with the present results showing that D-Lys3-GHRP-6
reduced the stimulatory action of ghrelin on osteoblast via-
bility. Furthermore, upregulation of phosphorylation ofGSK-
𝛽/𝛽-catenin signaling in the presence of GHS-R1a protected
neonatal rats from hypoxia-induced pulmonary hyperten-
sion [27].
Stimulation of ghrelin receptor leads to activation ofmul-
tiple downstream signaling.
Kim and colleagues [6] have shown that ghrelin promotes
osteoblast proliferation and differentiation through MAPK/
ERKandPI3K/AKT signaling pathways, but cAMP-mediated
PKA pathway was not examined. It is likely that the effects
of ghrelin on 𝛽-catenin accumulation involve PKA activation
since inhibition of the enzyme activity by H89 abrogated
the stimulatory action of ghrelin on 𝛽-catenin levels. Any
potential bias due to the effect of H89 on cell differentiation
was controlled by the short term (1 hour) exposure of
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Figure 7: Effect of conditioned media (CM) obtained from rat osteoblast-like cells (rOB) treated without or with ghrelin (AG, 10−10M for
24 or 48 h) on osteoclast formation, in presence of 50 ng/mL RANKL and 25 ng/mL M-CSF. Black arrows: multinucleated tartrate-resistant
acid phosphatase positive (TRAP+) cells (a). The percentage of TRAP+ multinucleated cells (≥3 nuclei) formed after 7 days culture with
conditionedmedia obtained from untreated and treated (AG, 10−10M for 24 or 48) rOB (b). ∗𝑃 < 0.05 versus CM of untreated cells; $𝑃 < 0.05
versus CM of rOB treated for 24 h with AG.
the cultures. It remains to be clarified whether ghrelin-
induced 𝛽-catenin stabilization via cAMP-dependent protein
kinase activation involves only the inhibition of GSK-3𝛽.
A number of recent reports showed that the phospho-
rylation of 𝛽-catenin on ser552 by PKA enhances the tran-
scriptional ability of 𝛽-catenin independent of the phospho-
rylation of 𝛽-catenin in the N-terminal domain at canonical
sites regulated by Wnt pathway [32, 33]. This molecular
mechanism of PKA-dependent 𝛽-catenin stabilization could
be involved in ghrelin-induced𝛽-catenin cytoplasmatic accu-
mulation. Our data show that ghrelin enhances rOB viability
through GHSR1a and PKA activation and, by acting on the
same pathways, promotes stabilization of intracellular 𝛽-
catenin levels. Therefore, we can speculate that the anabolic
action of ghrelin in rOB is exerted through 𝛽-catenin
stabilization. Further studies will be required to examine
the direct involvement of 𝛽-catenin stabilization in ghrelin
enhancement of rOB viability.
Loss- and gain-of-function mutations of 𝛽-catenin in
osteoblasts affect not only bone formation but also bone
resorption and osteoclast differentiation due to deregulation
of the OPG gene. Activation of theWnt/𝛽-catenin pathway in
osteoblasts suppresses bone resorption through upregulation
of OPG expression and downregulation of RANKL expres-
sion [34, 35].
Our results show that ghrelin stimulates OPG expression
and that pretreatment with the GHS-R1a antagonist, D-Lys3-
GHRP-6, abolished the stimulatory action of ghrelin onOPG,
thus indicating that ghrelin effects on OPG are specific and
receptor mediated. The evidence that ghrelin induces OPG
gene expression and reduces RANKL/OPG ratio suggests for
the peptide an inhibitory role on osteoclastogenesis. This
assumption is in line with the results obtained by exposing
bone marrow precursor cells to the conditioned medium
after 24 hr and 48 hr treatment with ghrelin. As expected,
from the understanding of the OPG/RANK/RANKL system
[36], we found that conditioned media from rOB treated
with ghrelin inhibited, indeed, the development of TRAcP+
cells from bone marrow precursors. In Figure 7, panel A,
typical multinucleated osteoclasts are outlined in the three
experimental conditions and quantified in panel B.
It remains to be clarified whether ghrelin could have
a direct action on osteoclastogenesis since the peptide
is present in conditioned medium (CM) from rOB. This
hypothesis is unlikely because CM from 24 h treated cells had
no effect on multinucleated TRAcP positive cell formation.
Consistent with this view is the here observed presence of the
effect at 48 hours (Figure 7) that follows the earlier reduction
of RANKL/OPG ratio at 24 h (Figure 6(c)), and the absence
of a stimulatory effect by ghrelin on osteoclast differentiation
observed by others in mouse bone marrow cultures [8].
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Our data show a stimulatory action of ghrelin onOPG ex-
pression and consequently an inhibition of osteoblast medi-
ated osteoclastogenesis and corroborate the results of Del-
hanty and colleagues [37] that demonstrated that osteoclas-
togenesis was faster in bone marrow cultures from ghrelin
receptor deficient and ghrelin deficient mice and that ghrelin
induced OPG expression in mouse osteoblastic cultures.
Since D-Lys3-GHRP-6 abolished ghrelin effect on OPG
expression in rOB, we can speculate that ghrelin affects
indirectly osteoclastogenesis by binding GHS-R1a in primary
rat osteoblasts. Our findings are in line with previous in
vivo studies with hexarelin, a synthetic GH secretagogue
that recognizes GHS-R1a. It has been reported, in fact, that
long-term hexarelin administration inhibits bone resorption
induced by gonadectomy in the rat [14]. Contrasting results
have been reported on the effects of ghrelin on osteoclast
activity. Costa and colleagues [8] have shown that ghrelin
at a concentration of 10−9M increased the bone resorption
activity ofmature rat osteoclasts but did notmodify osteoclast
differentiation in mouse bone marrow cultures. However,
the conditioned medium used in our experimental condi-
tion mimics the inhibitory effect of OPG addition in the
osteoclastogenesis assay applied by Costa et al. [8]. More
recently, van der Velde and colleagues [11] reported that ghre-
lin has a direct negative effect and indirect age-dependent
positive action on osteoclastogenesis via a systemic pathway
that is controlled by leptin. The importance of ghrelin in
contrasting the “ageing” effect could be confirmed by our very
preliminary data indicating that ghrelin (10−8M) induces
a global hypermethylation of primary rat osteoblasts DNA
(data not shown). This effect might counteract the typical
global hypomethylation of DNA present in postmenopausal
women with osteoporosis [38].
More research on this complex but fascinating area of
gerontology and future in vitro and in vivo studies will be
required to clarify the role of ghrelin in the regulation of bone
turnover and to suggest the potential utility of GHS-R1a-
agonists to stimulate bone formation and to inhibit osteoclas-
togenesis, thus improving bone structure in conditions such
as osteoporosis.
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